<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363294</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2020-0386</org_study_id>
    <nct_id>NCT04363294</nct_id>
  </id_info>
  <brief_title>Targeted Testing for ATTR Among Aortic Stenosis Patients-Pilot</brief_title>
  <official_title>Targeted Testing for Transthyretin Cardiac Amyloid Among Aortic Stenosis Patients-Pilot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mid America Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our ultimate goal is to design a multi-center randomized trial to test the hypothesis that&#xD;
      targeted testing for transthyretin cardiac amyloid (ATTR) will improve survival and health&#xD;
      status among aortic stenosis patients who undergo transcatheter aortic valve replacement&#xD;
      (TAVR). The hypothesis of this pilot study is to evaluate if invasive cardiac hemodynamics&#xD;
      obtained after TAVR, by using the AortoVentricular index (AVi), can be used as a novel test&#xD;
      to help identify participants with ATTR.&#xD;
&#xD;
      Aim 1. To determine if an abnormal AVi value can identify ATTR among aortic stenosis patients&#xD;
      undergoing TAVR.&#xD;
&#xD;
      Aim 2. To determine if s' from echocardiography plus AVi can enhance the prediction of ATTR&#xD;
      among aortic stenosis patients undergoing TAVR.&#xD;
&#xD;
      Aim 3. To design a pilot trial to improve patient outcomes after TAVR by targeted testing for&#xD;
      ATTR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1. To determine if an abnormal AVi value can identify ATTR among aortic stenosis patients&#xD;
      undergoing TAVR. Patients undergoing TAVR for symptomatic severe aortic stenosis, with&#xD;
      pre-TAVR echocardiography and post-implantation invasive hemodynamic assessment are eligible&#xD;
      for study participation. The AVi will be recorded from post-implantation invasive hemodynamic&#xD;
      assessment. Participants will undergo bone scintigraphy (99mTc-pyrophosphate Planar/SPECT&#xD;
      imaging) within 28 days after TAVR. Participants with abnormal bone scintigraphy require&#xD;
      evaluation for a monoclonal protein with blood/urine laboratory testing, and possible tissue&#xD;
      biopsy/Hematology consultation to exclude light-chain amyloidosis. Participants who are ATTR&#xD;
      positive will receive comprehensive heart failure management and possible genetic testing to&#xD;
      evaluate for mutated ATTR. The prevalence of ATTR will be reported among participants with&#xD;
      AVi &lt;0.5 versus ≥0.5 mm Hg/beats per minute. Test performance of AVi to predict ATTR will be&#xD;
      reported.&#xD;
&#xD;
      Aim 2. To determine if s' obtained from echocardiography tissue Doppler imaging plus AVi can&#xD;
      enhance the prediction of ATTR among aortic stenosis patients undergoing TAVR. The s' will be&#xD;
      recorded from pre-TAVR tissue Doppler imaging of the mitral annulus. The prevalence of ATTR&#xD;
      will be reported among participants with both s' ≤6 cm/second and AVi &lt;0.5 mm Hg/beats per&#xD;
      minute versus s' &gt;6 cm/second and AVi &lt;0.5 mm Hg/beats per minute.&#xD;
&#xD;
      Aim 3. To design a pilot trial to improve patient outcomes after TAVR by targeted testing for&#xD;
      ATTR. The change in Kansas City Cardiomyopathy Questionnaire-12 from baseline to 12-months&#xD;
      and survival with reasonable quality of life at 12-months will be reported among participants&#xD;
      who are ATTR positive vs. ATTR negative.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    grant was not approved, no subjects enrolled&#xD;
  </why_stopped>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants undergoing TAVR for symptomatic severe aortic stenosis, with pre-TAVR echocardiography and post-implantation invasive hemodynamic assessment are eligible for study participation. The AVi will be recorded from post-implantation invasive hemodynamic assessment. Participants will undergo bone scintigraphy (99mTc-pyrophosphate Planar/SPECT imaging) within 28 days after TAVR. Participants with abnormal bone scintigraphy require evaluation for a monoclonal protein with blood/urine laboratory testing, and possible tissue biopsy/Hematology consultation to exclude light-chain amyloidosis. Participants who are ATTR positive will receive comprehensive heart failure management and possible genetic testing to evaluate for mutated ATTR.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence ATTR with AVi &lt;0.5</measure>
    <time_frame>Within 28 days after TAVR when bone scan completed</time_frame>
    <description>Prevalence of ATTR among participants with AVi &lt;0.5 mm Hg/beats per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence ATTR with AVi ≥0.5</measure>
    <time_frame>Within 28 days after TAVR when bone scan completed</time_frame>
    <description>Prevalence of ATTR among participants with AVi ≥0.5 mm Hg/beats per minute</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity AVi</measure>
    <time_frame>Within 28 days after TAVR when bone scan completed</time_frame>
    <description>Sensitivity of AVi &lt;0.5 mm Hg/beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity AVi</measure>
    <time_frame>Within 28 days after TAVR when bone scan completed</time_frame>
    <description>Specificity of AVi ≥0.5 mm Hg/beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value AVi</measure>
    <time_frame>Within 28 days after TAVR when bone scan completed</time_frame>
    <description>Positive predictive value of AVi &lt;0.5 at predicting ATTR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value AVi</measure>
    <time_frame>Within 28 days after TAVR when bone scan completed</time_frame>
    <description>Negative predictive value of AVi ≥0.5 at ruling out ATTR</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Prevalence ATTR with s'&lt;6 plus AVi &lt;0.5</measure>
    <time_frame>Within 28 days after TAVR when bone scan completed</time_frame>
    <description>Prevalence of ATTR among participants with both s'&lt;6 and AVi &lt;0.5 mm Hg/beats per minute</description>
  </other_outcome>
  <other_outcome>
    <measure>Prevalence ATTR with s'≥6 plus AVi &lt;0.5</measure>
    <time_frame>Within 28 days after TAVR when bone scan completed</time_frame>
    <description>Prevalence of ATTR among participants with both s'≥6 and AVi &lt;0.5 mm Hg/beats per minute</description>
  </other_outcome>
  <other_outcome>
    <measure>KCCQ-12</measure>
    <time_frame>1 year after TAVR</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire(KCCQ) - a shortened 12 question version of the 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </other_outcome>
  <other_outcome>
    <measure>Favorable outcome</measure>
    <time_frame>1 year after TAVR</time_frame>
    <description>Proportion of subjects who are alive with reasonable quality of life. Reasonable quality of life is defined as KCCQ-12 ≥60 without any meaningful worsening (decrease in KCCQ-12 summary score ≥10).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Cardiac Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Participants</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who had TAVR and underwent evaluation for ATTR with PYP scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PYP scan</intervention_name>
    <description>99mTc-labeled pyrophosphate</description>
    <arm_group_label>Participants</arm_group_label>
    <other_name>Bone scan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Successful implantation of a transcatheter heart valve with a commercially available&#xD;
             valve (i.e. Sapien 3, Sapien Ultra, Evolut R, Evolut Pro, Evolut Pro+, or Lotus Edge)&#xD;
             for native or bioprosthetic aortic stenosis&#xD;
&#xD;
          -  Pre-implantation echocardiography with tissue Doppler imaging, if feasible&#xD;
&#xD;
          -  Post-implantation invasive cardiac hemodynamics&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;75 years&#xD;
&#xD;
          -  Moderate to severe paravalvular aortic regurgitation on post-operative&#xD;
             echocardiography&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony A Bavry, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Anthony Bavry</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>aortic stenosis</keyword>
  <keyword>transthyretin cardiac amyloid</keyword>
  <keyword>transcatheter aortic valve replacement</keyword>
  <keyword>AortoVentricular index</keyword>
  <keyword>ATTR</keyword>
  <keyword>TAVR</keyword>
  <keyword>AVi</keyword>
  <keyword>invasive cardiac hemodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The primary investigator will upload de-identified individual data after study results have been published</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will become available after study results have been published</ipd_time_frame>
    <ipd_access_criteria>The primary investigator will upload study protocol, statistical analysis plan, informed consent form, and clinical study report after study results have been published</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

